Literature DB >> 11815594

Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection.

Ashraf A F Elsaghier1, Hazel M Aucken, Jeremy M Hamilton-Miller, Stephen Shaw, Christopher C Kibbler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815594     DOI: 10.1093/jac/49.2.423

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  5 in total

1.  Characterisation of methicillin-resistant Staphylococcus aureus with reduced susceptibility to teicoplanin in Eastern France.

Authors:  X Bertrand; D Hocquet; M Thouverez; P Plésiat; D Talon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-12       Impact factor: 3.267

2.  Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from 1986 to 2001.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Wen-Hwei Chen; Huei-Ju Pan; Mei-Lin Chen; Shan-Chwen Chang; Kwen-Tay Luh; Fang-Yue Lin
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 3.  Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections.

Authors:  Natasha E Holmes; Paul D R Johnson; Benjamin P Howden
Journal:  J Clin Microbiol       Date:  2012-05-16       Impact factor: 5.948

4.  Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Authors:  Federico Pea; Pierluigi Viale; Anna Candoni; Federica Pavan; Leonardo Pagani; Daniela Damiani; Marco Casini; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India.

Authors:  Yamuna Devi Bakthavatchalam; Priyanka Babu; Elakkiya Munusamy; Hariharan Triplicane Dwarakanathan; Priscilla Rupali; Marcus Zervos; Peter John Victor; Balaji Veeraraghavan
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.